REsults of LOw Anterior Resections With or Without Preventive Stoma in Nonemergency Department

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorANO Scientific and Practical Club for the Development of Modern Medical Technologies

About this trial

The purpose of this multicenter randomized non-inferiority trial is to evaluate the safety of low anterior resection for rectal cancer performed with versus without a diverting stoma in patients with a low predicted risk of colorectal anastomotic leakage.

The primary objective is to determine whether the rate of anastomotic leakage within 30 days after surgery in the no-stoma group is non-inferior to that in the diverting stoma group.

The secondary objectives include comparison between groups regarding: Stoma rate at 1 year after surgery; Quality of life at 30 days and 1 year (EORTC QLQ-C30, EORTC QLQ-CR29, and LARS score); Short-term postoperative outcomes, including postoperative day metrics, length of hospital stay, and complications graded according to the Clavien-Dindo classification; Reoperation rates within 30 days and 1 year.

Participants will include adult patients with mid- or low-rectal adenocarcinoma who are scheduled for radical minimally invasive total mesorectal excision and have a predicted risk of anastomotic leakage \<10% according to the study risk model.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age >18 years;

Primary rectal cancer staged as cT1-4aN0-3M0 (or ycT0-4aN0-2M0);

Histologically confirmed rectal adenocarcinoma based on endoscopic biopsy;

Tumor located ≤12 cm from the dentate line (based on endoscopy, digital rectal examination, and/or pelvic MRI);

Disqualifiers

Age ≥80 years;

Presence of a pre-existing diverting ileostomy or colostomy;

Peritumoral abscess or tumor perforation;

Distant metastases (M1) identified preoperatively and/or intraoperatively;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Without a preventive stoma

    Procedure/Surgery

    At the conclusion of total mesorectal excision (TME), a diverting ileostomy or transverse colostomy will be created at the discretion of the operating surgeon. The pelvic peritoneum over the anastomotic site will be closed, and a pelvic drain will be placed (the type of drain will be determined by the operating surgeon).

  • With a preventive stoma

    Procedure/Surgery

    The operating surgeon will follow the standard practice adopted at the respective center and will create either a diverting ileostomy or transverse colostomy at their discretion. The pelvic peritoneum will not be closed. Placement of a percutaneous pelvic drain adjacent to the anastomotic site is mandatory.

Treatment groups

442 Participants
are divided into 2 treatment groups
Group A: Without a preventive stomaExperimental treatment 1 intervention
Group B: With a preventive stomaActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Colorectal anastomotic leak

If anastomotic leakage is suspected in the postoperative period defined by worsening abdominal pain (\>5-point increase on the Visual Analog Scale), signs of peritonitis, drain output containing fibrin or intestinal content, or radiologic findings suggestive of leakage on contrast-enhanced CT of the abdomen and pelvis (with or without proctography) and/or findings at diagnostic laparoscopy. Diagnostic and/or therapeutic measures will be undertaken to confirm or rule out the complication.

Time frame
30 days after main surgery

Secondary outcomes

1

Postoperative complications

Postoperative complications will be classified according to the Clavien-Dindo classification

Time frame
30 days after main surgery
2

Reoperation rate

During a clinic visit or by telephone interview

Time frame
30 days and 1 year after main surgery
3

Stoma rate

During a clinic visit or by telephone interview

Time frame
1 year after main surgery
4

Hospital readmissions

The frequency of repeated admissions to this or other hospitals after the patient's discharge

Time frame
30 days after main surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.